DOW JONES22,348.50+711.72 3.29%
S&P 5002,629.21+87.74 3.45%
NASDAQ7,774.15+271.77 3.62%

AzurRx BioPharma Says On Mar. 11 Provided TransChem With 60 Day Notice Of Intent To Terminate Sublicene Agreement

On March 11, 2020, AzurRx BioPharma, Inc. (the “Company”) provided TransChem, Inc. (“TransChem”) with sixty (60) days prior written notice of its intent to terminate the sublicene agreement dated

Benzinga · 03/16/2020 21:17

On March 11, 2020, AzurRx BioPharma, Inc. (the “Company”) provided TransChem, Inc. (“TransChem”) with sixty (60) days prior written notice of its intent to terminate the sublicene agreement dated January 14, 2017 between TransChem and the Company (the “Sublicense Agreement”). The Sublicense Agreement and the licenses granted thereunder related to Helicobacter pylori (“H. pylori”) 5’methylthioadenosine nucleosidase inhibitors in preclinical development.
The Company is focusing its resources on the development of its lead drug product candidate, MS1819, in Phase II clinical trials for the treatment of exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis and chronic pancreatitis.
The information in this Current Report on Form 8-K is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.